{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T21:01:43Z","timestamp":1770066103801,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["GCE-INDIA\/R4\/2018\/007."],"award-info":[{"award-number":["GCE-INDIA\/R4\/2018\/007."]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Antibiot"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1038\/s41429-024-00748-w","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T09:02:36Z","timestamp":1718614956000},"page":"612-626","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Reversal of carbapenem resistance in Pseudomonas aeruginosa by camelid single domain antibody fragment (VHH) against the C4-dicarboxylate transporter"],"prefix":"10.1038","volume":"77","author":[{"given":"Anil Kumar","family":"Nagraj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manjiri","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mansi","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pratik","family":"Patil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mrunal","family":"Borgave","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0643-1680","authenticated-orcid":false,"given":"Sanjiban K.","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,17]]},"reference":[{"key":"748_CR1","doi-asserted-by":"publisher","unstructured":"De Oliveira DMP, Forde BM, Kidd TJ, Harris PNA, Schembri MA, Beatson SA, Paterson DL, Walker MJ. Antimicrobial Resistance in ESKAPE Pathogens. Clin Microbiol Rev. 2020;33.\u00a0https:\/\/doi.org\/10.1128\/CMR.00181-19","DOI":"10.1128\/CMR.00181-19"},{"key":"748_CR2","unstructured":"Centers for Disease Control and Prevention (U.S.). Antibiotic resistance threats in the United States, 2019. Centers for Disease Control and Prevention (U.S.); 2019."},{"key":"748_CR3","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12890-016-0339-5","volume":"16","author":"AY Bhagirath","year":"2016","unstructured":"Bhagirath AY, Li Y, Somayajula D, Dadashi M, Badr S, Duan K. Cystic fibrosis lung environment and Pseudomonas aeruginosa infection. BMC Pulm Med. 2016;16:174.","journal-title":"BMC Pulm Med"},{"key":"748_CR4","doi-asserted-by":"publisher","first-page":"605195","DOI":"10.1155\/2011\/605195","volume":"2011","author":"TS Sivanmaliappan","year":"2011","unstructured":"Sivanmaliappan TS, Sevanan M. Antimicrobial susceptibility patterns of pseudomonas aeruginosa from diabetes patients with foot ulcers. Int J Microbiol. 2011;2011:605195.","journal-title":"Int J Microbiol"},{"key":"748_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.gendis.2019.04.001","volume":"6","author":"P Pachori","year":"2019","unstructured":"Pachori P, Gothalwal R, Gandhi P. Emergence of antibiotic resistance Pseudomonas aeruginosa in intensive care unit; a critical review. Genes Dis. 2019;6:109\u201319.","journal-title":"Genes Dis"},{"key":"748_CR6","doi-asserted-by":"publisher","first-page":"182","DOI":"10.4103\/0974-777X.145250","volume":"6","author":"N Rajkumari","year":"2014","unstructured":"Rajkumari N, John NV, Mathur P, Misra MC. Antimicrobial resistance in Pseudomonas sp. causing infections in trauma patients: a 6 year experience from a South Asian country. J Glob Infect Dis. 2014;6:182\u20135.","journal-title":"J Glob Infect Dis"},{"key":"748_CR7","doi-asserted-by":"publisher","first-page":"4943","DOI":"10.1128\/AAC.00296-11","volume":"55","author":"KM Papp-Wallace","year":"2011","unstructured":"Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011;55:4943\u201360.","journal-title":"Antimicrob Agents Chemother"},{"key":"748_CR8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2147\/IDR.S233808","volume":"13","author":"NA Hassuna","year":"2020","unstructured":"Hassuna NA, Darwish MK, Sayed M, Ibrahem RA. Molecular epidemiology and mechanisms of high-level resistance to meropenem and imipenem in Pseudomonas aeruginosa. Infect Drug Resist. 2020;13:285\u201393.","journal-title":"Infect Drug Resist"},{"key":"748_CR9","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.2174\/0929867322666150417122531","volume":"22","author":"A Dorotkiewicz-Jach","year":"2015","unstructured":"Dorotkiewicz-Jach A, Augustyniak D, Olszak T, Drulis-Kawa Z. Modern therapeutic approaches against Pseudomonas aeruginosa infections. Curr Med Chem. 2015;22:1642\u201364.","journal-title":"Curr Med Chem"},{"key":"748_CR10","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/363446a0","volume":"363","author":"C Hamers-Casterman","year":"1993","unstructured":"Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, et al. Naturally occurring antibodies devoid of light chains. Nature 1993:363:446\u20138. https:\/\/doi.org\/10.1038\/363446a0","journal-title":"Nature"},{"key":"748_CR11","doi-asserted-by":"publisher","first-page":"26285","DOI":"10.1074\/jbc.M102107200","volume":"276","author":"A Desmyter","year":"2001","unstructured":"Desmyter A, Decanniere K, Muyldermans S, Wyns L. Antigen specificity and high-affinity binding provided by one single loop of a camel single-domain antibody. J Biol Chem. 2001;276:26285\u201390.","journal-title":"J Biol Chem"},{"key":"748_CR12","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","volume":"82","author":"S Muyldermans","year":"2013","unstructured":"Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013;82:775\u201397.","journal-title":"Annu Rev Biochem"},{"key":"748_CR13","doi-asserted-by":"publisher","first-page":"13626","DOI":"10.1074\/jbc.RA118.003888","volume":"293","author":"MT King","year":"2018","unstructured":"King MT, Huh I, Shenai A, Brooks TM, Brooks CL. Structural basis of VHH-mediated neutralization of the food-borne pathogen Listeria monocytogenes. J Biol Chem. 2018;293:13626\u201335.","journal-title":"J Biol Chem"},{"key":"748_CR14","doi-asserted-by":"publisher","first-page":"e12584","DOI":"10.1111\/pim.12584","volume":"40","author":"C Abeijon","year":"2018","unstructured":"Abeijon C, Dilo J, Tremblay JM, Viana AG, Bueno LL, Carvalho SFG, et al. Use of VHH antibodies for the development of antigen detection test for visceral leishmaniasis. Parasite Immunol. 2018;40:e12584.","journal-title":"Parasite Immunol"},{"key":"748_CR15","doi-asserted-by":"publisher","unstructured":"Wrapp D, De Vlieger D, Corbett KS, Torres GM, Wang N, Van Breedam W, et al. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies. Cell 2020;181:1004\u201315.e15. https:\/\/doi.org\/10.1016\/j.cell.2020.04.031","DOI":"10.1016\/j.cell.2020.04.031"},{"key":"748_CR16","doi-asserted-by":"crossref","unstructured":"Jov\u010devska I, Muyldermans S. The Therapeutic Potential of Nanobodies. BioDrugs. 2020;34:11\u201326.","DOI":"10.1007\/s40259-019-00392-z"},{"key":"748_CR17","doi-asserted-by":"publisher","unstructured":"Duggan S. Caplacizumab: First Global Approval. Drugs. 2018;78:1639\u201342. https:\/\/doi.org\/10.1007\/s40265-018-0989-0.","DOI":"10.1007\/s40265-018-0989-0"},{"key":"748_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.vetimm.2011.04.004","volume":"142","author":"AQ Abbady","year":"2011","unstructured":"Abbady AQ, Al-Mariri A, Zarkawi M, Al-Assad A, Muyldermans S. Evaluation of a nanobody phage display library constructed from a Brucella-immunised camel. Vet Immunol Immunopathol. 2011;142:49\u201356.","journal-title":"Vet Immunol Immunopathol"},{"key":"748_CR19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12865-015-0113-0","volume":"16","author":"CP Corkum","year":"2015","unstructured":"Corkum CP, Ings DP, Burgess C, Karwowska S, Kroll W, Michalak TI. Immune cell subsets and their gene expression profiles from human PBMC isolated by Vacutainer Cell Preparation Tube (CPTTM) and standard density gradient. BMC Immunol. 2015;16:48.","journal-title":"BMC Immunol"},{"key":"748_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1128\/jcm.16.1.141-144.1982","volume":"16","author":"BL Elder","year":"1982","unstructured":"Elder BL, Boraker DK, Fives-Taylor PM. Whole-bacterial cell enzyme-linked immunosorbent assay for Streptococcus sanguis fimbrial antigens. J Clin Microbiol. 1982;16:141\u20134.","journal-title":"J Clin Microbiol"},{"key":"748_CR21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nprot.2007.521","volume":"3","author":"I Wiegand","year":"2008","unstructured":"Wiegand I, Hilpert K, Hancock REW. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc. 2008;3:163\u201375.","journal-title":"Nat Protoc"},{"key":"748_CR22","unstructured":"M100Ed32 | Performance Standards for Antimicrobial Susceptibility Testing, 32nd Edition. Clinical & Laboratory Standards Institute n.d. https:\/\/clsi.org\/standards\/products\/microbiology\/documents\/m100\/"},{"key":"748_CR23","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1093\/jac\/dkn133","volume":"62","author":"BT Tsuji","year":"2008","unstructured":"Tsuji BT, Yang JC, Forrest A, Kelchlin PA, Smith PF. In vitro pharmacodynamics of novel rifamycin ABI-0043 against Staphylococcus aureus. J Antimicrob Chemother. 2008;62:156\u201360.","journal-title":"J Antimicrob Chemother"},{"key":"748_CR24","doi-asserted-by":"publisher","unstructured":"Marshall RL, Lloyd GS, Lawler AJ, Element SJ, Kaur J, Ciusa ML, et al. New Multidrug Efflux Inhibitors for Gram-Negative Bacteria. mBio 2020;11:e01340\u201320. https:\/\/doi.org\/10.1128\/mBio.01340-20","DOI":"10.1128\/mBio.01340-20"},{"key":"748_CR25","doi-asserted-by":"publisher","first-page":"4307","DOI":"10.1128\/JB.05074-11","volume":"193","author":"M Valentini","year":"2011","unstructured":"Valentini M, Storelli N, Lapouge K. Identification of C4-Dicarboxylate Transport Systems in Pseudomonas aeruginosa PAO1 J Bacteriol. 2011;193:4307\u201316.","journal-title":"J Bacteriol"},{"key":"748_CR26","doi-asserted-by":"publisher","unstructured":"Secher T, Fas S, Fauconnier L, Mathieu M, Rutschi O, Ryffel B, et al. The anti-Pseudomonas aeruginosa antibody Panobacumab is efficacious on acute pneumonia in neutropenic mice and has additive effects with meropenem. PloS one 2013;8:e73396. https:\/\/doi.org\/10.1371\/journal.pone.0073396","DOI":"10.1371\/journal.pone.0073396"},{"key":"748_CR27","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1146\/annurev-micro-090817-062257","volume":"72","author":"SK Dolan","year":"2018","unstructured":"Dolan SK, Welch M. The Glyoxylate Shunt, 60 Years On. Annu Rev Microbiol. 2018;72:309\u201330.","journal-title":"Annu Rev Microbiol"},{"key":"748_CR28","doi-asserted-by":"crossref","unstructured":"Ahn S, Jung J, Jang IA, Madsen EL, Park W. Role of Glyoxylate Shunt in Oxidative Stress Response. J Biol Chem. 2016;291:11928\u201338.","DOI":"10.1074\/jbc.M115.708149"},{"key":"748_CR29","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.cell.2007.06.049","volume":"130","author":"MA Kohanski","year":"2007","unstructured":"Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA, Collins JJ. A common mechanism of cellular death induced by bactericidal antibiotics. Cell. 2007;130:797\u2013810.","journal-title":"Cell"},{"key":"748_CR30","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.cmi.2017.08.026","volume":"23","author":"OJ Dyar","year":"2017","unstructured":"Dyar OJ, Huttner B, Schouten J, Pulcini C; ESGAP (ESCMID Study Group for Antimicrobial stewardship). What is antimicrobial stewardship? Clin Microbiol Infect. 2017;23:793\u20138.","journal-title":"Clin Microbiol Infect"},{"key":"748_CR31","first-page":"60","volume":"25","author":"E Pelfrene","year":"2019","unstructured":"Pelfrene E, Mura M, Cavaleiro Sanches A, Cavaleri M. Monoclonal antibodies as anti-infective products: a promising future? Clin Microbiol Infect. 2019;25:60\u20134.","journal-title":"Microbiol Infect"},{"key":"748_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12934-019-1094-0","volume":"18","author":"D Ruano-Gallego","year":"2019","unstructured":"Ruano-Gallego D, Fraile S, Gutierrez C, Fern\u00e1ndez L\u00c1. Screening and purification of nanobodies from E. coli culture supernatants using the hemolysin secretion system. Micro Cell Fact. 2019;18:47.","journal-title":"Micro Cell Fact"},{"key":"748_CR33","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.3389\/fimmu.2017.01802","volume":"8","author":"Y Wu","year":"2017","unstructured":"Wu Y, Jiang S, Ying T. Single-domain antibodies as therapeutics against human viral diseases. Front Immunol. 2017;8:1802.","journal-title":"Front Immunol"},{"key":"748_CR34","doi-asserted-by":"publisher","first-page":"e28309","DOI":"10.1371\/journal.pone.0028309","volume":"6","author":"G Wei","year":"2011","unstructured":"Wei G, Meng W, Guo H, Pan W, Liu J, Peng T, et al. Potent neutralization of influenza A virus by a single-domain antibody blocking M2 ion channel protein. PLoS ONE. 2011;6:e28309. https:\/\/doi.org\/10.1371\/journal.pone.0028309","journal-title":"PLoS ONE"},{"key":"748_CR35","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1128\/AAC.01802-15","volume":"60","author":"L Detalle","year":"2016","unstructured":"Detalle L, Stohr T, Palomo C, Piedra PA, Gilbert BE, Mas V, et al. Generation and characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection. Antimicrob Agents Chemother. 2015;60:6\u201313. https:\/\/doi.org\/10.1128\/AAC.01802-15","journal-title":"Antimicrob Agents Chemother"},{"key":"748_CR36","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.3389\/fmicb.2019.02665","volume":"10","author":"J Huen","year":"2019","unstructured":"Huen J, Yan Z, Iwashkiw J, Dubey S, Gimenez MC, Ortiz ME, et al. A novel single domain antibody targeting FliC flagellin of Salmonella enterica for effective inhibition of host cell invasion. Front Microbiol. 2019;10:2665. https:\/\/doi.org\/10.3389\/fmicb.2019.02665","journal-title":"Front Microbiol"},{"key":"748_CR37","doi-asserted-by":"publisher","first-page":"6191","DOI":"10.1128\/JB.01651-09","volume":"192","author":"LR Mulcahy","year":"2010","unstructured":"Mulcahy LR, Burns JL, Lory S, Lewis K. Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. J Bacteriol. 2010;192:6191\u20139.","journal-title":"J Bacteriol"},{"key":"748_CR38","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/S2666-5247(22)00329-9","volume":"4","author":"J Reyes","year":"2023","unstructured":"Reyes J, Komarow L, Chen L, Ge L, Hanson BM, Cober E, et al. Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study. Lancet Microbe. 2023;4:e159\u201370.","journal-title":"Lancet Microbe"},{"key":"748_CR39","doi-asserted-by":"publisher","first-page":"53","DOI":"10.51620\/0869-2084-2022-67-1-53-58","volume":"67","author":"ME Ivanov","year":"2022","unstructured":"Ivanov ME, Fursova NK, Potapov VD. Pseudomonas aeruginosa efflux pump superfamily (review of literature). Klin Lab Diagn. 2022;67:53\u20138.","journal-title":"Klin Lab Diagn"},{"key":"748_CR40","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1007\/s10096-011-1509-2","volume":"31","author":"Y Song","year":"2012","unstructured":"Song Y, Baer M, Srinivasan R, Lima J, Yarranton G, Bebbington C, et al. PcrV antibody-antibiotic combination improves survival in Pseudomonas aeruginosa-infected mice. Eur J Clin Microbiol Infect Dis. 2012;31:1837\u201345. https:\/\/doi.org\/10.1007\/s10096-011-1509-2","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"748_CR41","doi-asserted-by":"publisher","unstructured":"P\u00e9rez-Cobas AE, Gosalbes MJ, Friedrichs A, Knecht H, Artacho A, Eismann K, et al. Gut microbiota disturbance during antibiotic therapy: a multi-omic approach. Gut. 2013;62:1591\u20131601. https:\/\/doi.org\/10.1136\/gutjnl-2012-303184","DOI":"10.1136\/gutjnl-2012-303184"}],"container-title":["The Journal of Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41429-024-00748-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41429-024-00748-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41429-024-00748-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T23:02:52Z","timestamp":1724713372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41429-024-00748-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,17]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["748"],"URL":"https:\/\/doi.org\/10.1038\/s41429-024-00748-w","relation":{},"ISSN":["0021-8820","1881-1469"],"issn-type":[{"value":"0021-8820","type":"print"},{"value":"1881-1469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,17]]},"assertion":[{"value":"25 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AN declares that he has no conflict of interest or competing interests. MS declares that she has no conflict of interest. MK, PP, and MB declare no conflict of interest. SB declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All applicable international, national, and\/or institutional guidelines were followed. Experiments in AbGenics were carried out with Institutional Biosafety Committee Approvals. All animal experiments were approved by the ethics committee of PRADO Preclinical Research and Development Organisation (India) with all relevant ethical regulations for animal testing.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approvals and consent to participate"}}]}}